Treatment of onychomycosis in the diabetic patient population
- PMID: 12614976
- DOI: 10.1016/s1056-8727(02)00199-x
Treatment of onychomycosis in the diabetic patient population
Abstract
Onychomycosis is a common medical condition in patients with diabetes. Conflicting data exist as to whether diabetes predisposes patients to the disease. Controversy notwithstanding, patients with diabetes have several medical conditions (obesity, peripheral neuropathy, and retinopathy) that can inhibit the identification or mask the progression of fungal nail infections. In addition, vascular insufficiency, impaired wound healing, and compromised immunologic status associated with diabetic foot increase the risk of secondary infections in diabetic patients with onychomycosis. Such factors contribute to an increased morbidity and decreased quality of life in these patients and underscore the need for effective antifungal treatment. Oral antifungal agents are generally well tolerated, but serious adverse events independent of or associated with a number of significant drug interactions have been reported. The availability of a topical therapy, ciclopirox topical solution, 8% (Penlac Nail Lacquer), provides clinicians with an additional effective and well-tolerated treatment option. In order to further increase the efficacy of topical or oral treatment, mechanical intervention (e.g., debridement) may be combined with either of these options. Choice of appropriate treatment and careful monitoring of fungal nail infections can prevent significant morbidity in patients with diabetes.
Similar articles
-
A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes.Cutis. 2001 Aug;68(2 Suppl):17-22. Cutis. 2001. PMID: 11665724 Clinical Trial.
-
Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study.J Am Podiatr Med Assoc. 2007 May-Jun;97(3):195-202. doi: 10.7547/0970195. J Am Podiatr Med Assoc. 2007. PMID: 17507527 Clinical Trial.
-
Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.J Am Acad Dermatol. 2000 Oct;43(4 Suppl):S81-95. doi: 10.1067/mjd.2000.109069. J Am Acad Dermatol. 2000. PMID: 11051137
-
Ciclopirox nail lacquer solution 8% in the 21st century.J Am Acad Dermatol. 2000 Oct;43(4 Suppl):S96-102. doi: 10.1067/mjd.2000.109068. J Am Acad Dermatol. 2000. PMID: 11051138 Review.
-
Ciclopirox nail lacquer: a brush with onychomycosis.Cutis. 2001 Aug;68(2 Suppl):13-6. Cutis. 2001. PMID: 11665723 Review.
Cited by
-
Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review.J Foot Ankle Res. 2011 Dec 4;4:26. doi: 10.1186/1757-1146-4-26. J Foot Ankle Res. 2011. PMID: 22136082 Free PMC article.
-
Ultraviolet C inactivation of dermatophytes: implications for treatment of onychomycosis.Br J Dermatol. 2008 Jun;158(6):1239-46. doi: 10.1111/j.1365-2133.2008.08549.x. Epub 2008 Apr 10. Br J Dermatol. 2008. PMID: 18410410 Free PMC article.
-
Laser therapy for onychomycosis in patients with diabetes at risk for foot complications: study protocol for a randomized, double-blind, controlled trial (LASER-1).Trials. 2015 Mar 22;16:108. doi: 10.1186/s13063-015-0622-4. Trials. 2015. PMID: 25872590 Free PMC article. Clinical Trial.
-
Efinaconazole in the treatment of onychomycosis.Infect Drug Resist. 2015 Jun 1;8:163-72. doi: 10.2147/IDR.S69596. eCollection 2015. Infect Drug Resist. 2015. PMID: 26082652 Free PMC article. Review.
-
Common fungal infections of the feet in patients with diabetes mellitus.Drugs Aging. 2004;21(2):101-12. doi: 10.2165/00002512-200421020-00003. Drugs Aging. 2004. PMID: 14960127 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical